GAB1 – novel regulator of migration capacity and tonic AKT activity in CLL: Implications for combinatorial therapy with BCR inhibitors.

ŠEDA, Václav, Eva HOFERKOVÁ, Laura ONDRIŠOVÁ, Lenka KOŠŤÁLOVÁ, Sonali SHARMA, Tomáš LOJA, Daniel ZICHA, Jan VERNER, Šárka POSPÍŠILOVÁ, Yvona BRYCHTOVÁ, Anna PANOVSKÁ, Michael DOUBEK, Jiří MAYER and Marek MRÁZ. GAB1 – novel regulator of migration capacity and tonic AKT activity in CLL: Implications for combinatorial therapy with BCR inhibitors. In XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL). 2021.

Basic information

Original name

GAB1 – novel regulator of migration capacity and tonic AKT activity in CLL: Implications for combinatorial therapy with BCR inhibitors.

Authors

ŠEDA, Václav, Eva HOFERKOVÁ, Laura ONDRIŠOVÁ, Lenka KOŠŤÁLOVÁ, Sonali SHARMA, Tomáš LOJA, Daniel ZICHA, Jan VERNER, Šárka POSPÍŠILOVÁ, Yvona BRYCHTOVÁ, Anna PANOVSKÁ, Michael DOUBEK, Jiří MAYER and Marek MRÁZ

Edition

XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL), 2021

---

Other information

Type of outcome

Conference abstract

Confidentiality degree

is not subject to a state or trade secret

Organization unit

Central European Institute of Technology

---

Links

MUNI/A/1595/2020, interní kód MU	Name: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit VIII (Acronym: VýDiTeHeMa VIII) Investor: Masaryk University
NU20-03-00292, research and development project	Name: PRIORITIZACE KOMBINACÍ LÉČIV U CHRONICKÉ LYMFOCYTÁRNÍ LEUKÉMIE NA ZÁKLADĚ ANALÝZY ADAPTACE BUNĚK NA IBRUTINIB A IDELALISIB IN VIVO
802644, interní kód MU	Name: Signaling propensity in the microenvironment of B cell chronic lymphocytic leukemia (Acronym: LeukemiaEnviron) Investor: European Union, ERC (Excellent Science)